Secondary end points included overall survival (OS) and overall response rate (ORR) per IRC.
次要终点包括IRC评估的总生存期(OS)和总缓解率(ORR)。
The primary end point was overall response rate (ORR) per investigator assessment (RECIST 1.1).
主要研究终点为总缓解率(ORR),采用评价标准为RECIST 1.1。
Conclusions: in patients with advanced larynx and hypopharynx carcinomas, TPF induction chemotherapy was superior to the PF regimen in terms of overall response rate.
结论:进展期喉癌和咽喉癌患者中,TPF诱导化疗的总体反应率高于PF化疗方案。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果:在33个被评估的病人中,总的反应率为70%(完全反应率加未确定的完全反应率,45%),中位无进展生存期为16.5个月。
Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.
结果:在33个被评估的病人中,总的反应率为70%(完全反应率加未确定的完全反应率,45%),中位无进展生存期为16.5个月。
应用推荐